<p>Mumbai, Baltimore, April 11, 2019: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc&amp;rsquo;s (AbbVie) AndroGel 1.62%.</p><p>Lupin&amp;rsquo;s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie&amp;rsquo;s AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:</p><ul><li>Primary hypogonadism (congenital or acquired) and</li><li>Hypogonadotropic hypogonadism (congenital or acquired)</li></ul><p>Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018).</p>